A non-interventional prospective study of Early HER2-negative high-risk breast cancer and BRCA1/2 mutations prevalence in RussiA

Trial Identifier: D133HR00030
Sponsor: AstraZeneca
NCTID:: NCT05939128
Start Date: June 2023
Primary Completion Date: June 2027
Study Completion Date: June 2027
Condition: Breast Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Russia Arkhangelsk, Russia
Russia Barnaul, Russia
Russia Belgorod, Russia
Russia Chelyabinsk, Russia
Russia Ekaterinburg, Russia
Russia Grozny, Russia
Russia Irkutsk, Russia
Russia Kazan, Russia
Russia Khanty-Mansiysk, Russia
Russia Krasnodar, Russia
Russia Krasnoyarsk, Russia
Russia Moscow, Russia
Russia Nalchik, Russia
Russia Nyzhny Novgorod, Russia
Russia Ryazan, Russia
Russia Saint Petersburg, Russia
Russia Samara, Russia
Russia Severodvinsk, Russia
Russia Sochi, Russia
Russia Tomsk, Russia
Russia Ufa, Russia
Russia Vladivostok, Russia
Russia Yaroslavl, Russia